vTv Therapeutics Inc (VTVT) USD0.01 A

Sell:$16.85Buy:$23.15$0.27 (1.20%)

Prices delayed by at least 15 minutes
Sell:$16.85
Buy:$23.15
Change:$0.27 (1.20%)
Prices delayed by at least 15 minutes
Sell:$16.85
Buy:$23.15
Change:$0.27 (1.20%)
Prices delayed by at least 15 minutes

Company Information

About this company

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases. Its product pipeline includes TTP399, TTP273, HPP737 and HPP593. The lead product candidate, cadisegliatin (TTP399), is an orally administered, small-molecule, liver-selective glucokinase activator (GKA) that is a potential adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). HPP737 is an orally administered, non-central nervous system (non-CNS) penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and offers the potential for an improved tolerability profile and efficacy over commercially available PDE4 inhibitors. TTP273 is an oral, small molecule, glucagon-like peptide 1 (GLP-1) receptor agonist being evaluated for the treatment of type 2 diabetes mellitus. Its product pipeline also includes Azeliragon and HPP3033.

Key people

Paul Jai Sekhri
Chairman of the Board, President, Chief Executive Officer
Richard S. Nelson
Executive Vice President - Corporate Development, Director
Srinivas Akkaraju
Independent Director
Fahed Al Marzooqi
Independent Director
Raymond Cheong
Independent Director
Anne M. Phillips
Independent Director
Click to see more

Key facts

  • EPIC
    VTVT
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US9183852048
  • Market cap
    $65.55m
  • Employees
    23
  • Shares in issue
    2.61m
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.